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Abstract
High throughput random mutagenesis is a powerful tool to identify which residues are
important for the function of a protein, and gain insight into its structure-function relation.
The human muscle nicotinic acetylcholine receptor was used to test whether this technique
previously used for monomeric receptors can be applied to a pentameric ligand-gated ion
channel. A mutant library for the α1 subunit of the channel was generated by error-prone
PCR, and full length sequences of all 2816 mutants were retrieved using single molecule
real time sequencing. Each α1 mutant was co-transfected with wildtype β1, δ, and ε sub-
units, and the channel function characterized by an ion flux assay. To test whether the strat-
egy could map the structure-function relation of this receptor, we attempted to identify
mutations that conferred resistance to competitive antagonists. Mutant hits were defined as
receptors that responded to the nicotinic agonist epibatidine, but were not inhibited by either
α-bungarotoxin or tubocurarine. Eight α1 subunit mutant hits were identified, six of which
contained mutations at position Y233 or V275 in the transmembrane domain. Three single
point mutations (Y233N, Y233H, and V275M) were studied further, and found to enhance
the potencies of five channel agonists tested. This suggests that the mutations made the
channel resistant to the antagonists, not by impairing antagonist binding, but rather by pro-
ducing a gain-of-function phenotype, e.g. increased agonist sensitivity. Our data show that
random high throughput mutagenesis is applicable to multimeric proteins to discover novel
functional mutants, and outlines the benefits of using single molecule real time sequencing
with regards to quality control of the mutant library as well as downstream mutant data
interpretation.
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Introduction
Obtaining the detailed structure-function information that is needed in order to design ligands
to target multimeric transmembrane proteins remains challenging. Structure determination of
these proteins by X-ray crystallography or cryo-electronmicroscopy is a low-yield, slow tech-
nique. The identification of functionally important domains or residues in the protein is gener-
ally derived from site-directedmutagenesis followed by functional testing. This is also a labor-
intensive process, and therefore it is common to see studies limited to small sets of mutations,
often alanine scans, of regions hypothesized to be important. Carrying out unbiased, large scale
mutagenesis studies clearly requires high throughput (HT) techniques to be practicable.We
have previously applied HT mutagenesis by error-prone PCR to monomeric proteins, namely
the G protein-coupled human prostacyclin receptor and the ion channel anoctamin 1 (ANO1)
[1,2]. In both cases, we were able to identify residues important for receptor function and to
derive structure-functionrelationships in the absence of crystal structures. Error-prone ran-
dom PCR represents an HT-amenable approach to create large mutant libraries with coverage
of all amino acids of a protein’s coding region. The aim of this study was to expand the applica-
tion of the method to a multimeric protein, for which the pentameric human muscle nicotinic
acetylcholine receptor (nAChR) was chosen.
The adult form of the muscle nAChR consists of four different subunits forming a pentamer
around the channel pore, (α1)2β1δε, and each subunit contains four transmembrane stretches
[3–5]. The nicotinic channel is permeable to cations, and is activated by acetylcholine at the
neuromuscular junctions of skeletal muscle. The pentamer contains two orthosteric agonist
binding sites in the N-terminal extracellular domain, at the interfaces of the α1-ε and α1-δ sub-
units [4,5]. We decided to use this well-characterized channel to test our HT randommutagen-
esis strategy and its associated functional screen, and chose to mutate the subunit that provides
the principal side to both binding sites, i.e. the α1 subunit (457 amino acids). A library of 2816
mutant plasmids was generated and transiently transfected into cultured cells to allow us to
perform an ion flux assay. Conditions for this assay were established using the wildtype α1 sub-
unit co-transfectedwith a multigene-plasmid containing all three wildtype β1, δ, and ε sub-
units, and the nicotinic agonist epibatidine to activate the channel [6].
As a test of our HT mutagenesis strategy, we chose to search for mutations that conferred
resistance to α-bungarotoxin (α-BTX) or tubocurarine, two orthosteric nAChR blockers whose
binding determinants are well characterized [4,7,8]. α-BTX is a snake venom protein that
binds irreversibly to muscle nAChR. Residues important for its binding to the extracellular
domain of the mouse α1 subunit have been confirmed by the co-crystallizationdata by Delli-
santi et al. [9]. The small alkaloid ligand D-tubocurarinebinds reversibly. Again, several α1
subunit amino acids have been identified as important for tubocurarinebinding on the basis of
functional assays and confirmed by the crystal structure of tubocurarine bound to the ACh
binding protein, a snail soluble protein orthologous to the extracellular domain of nAChRs
[8,10,11]. α1 subunit mutants that still responded to the agonist, but had decreased sensitivity
to either inhibitor were identified in the screen, confirmed and further characterized.
The novelty of the present study lies not only in the application of HTmutagenesis to a mul-
timeric protein complex, but also in the first application of single molecule real time sequenc-
ing (SMRT) to sequence all the 2816 α1 subunit mutants. Mutant libraries had been previously
characterized using ‘Next Generation Sequencing’ (NGS) techniques, such as an Illumina 454
reader [1,2]. Illumina sequencing is based on the amplification of the cDNA molecules with an
engineeredDNA polymerase and can read stretches of 50–300 base pairs (bp). This implies
that a typical membrane protein such as the nAChR α1 subunit (1371 bp) needs to be
sequenced in multiple parallel reactions, and this makes it impossible to distinguish single
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plasmids within the pooledmutant library (Fig 1). On the other hand, the novel SMRT
sequencing using a PacBio RSII reader can read individual DNA molecules up to 40’000 bp
sequences in a single reaction, thereby preserving the information of the origin of each muta-
tion [12,13]. In the study describedhere, SMRT sequencing allowed us to see which mutations
occurred together on each single α1 subunit mutant cDNA plasmid, and hence to deconvolute
data from pooled plasmid sequencing.
Material and Methods
Cloning of wildtype subunit plasmids
The cDNAs for the four human muscle nAChR subunits α1 (CHRNA1, NM_000079.3), β1
(CHRNB1, NM_000747.2), δ (CHRND, NM_000751.2), and ε (CHRNE, NM_000080.3) were
synthesized by GENEWIZ (Europe), and a Kozak consensus sequence (GCCACC) was added
upstream of each start codon. cDNA sequences were cloned into cytomegalovirus promotor
(CMV)-driven single expression vectors. A triple multigene expression vector containing β1, δ,
and ε subunits, each linked to an elongation factor (EF)-1α promotor was engineered for com-
bination with a single CMV-dependent α1 subunit vector. Finally, a quadruple gene vector
containing the CMV-α1 expression cassette upstream of the EF1α-β1, EF1α-δ, and EF1α-ε
expression cassettes was created as a control (S1A Fig). All plasmid inserts were sequence-veri-
fied. Amino acid (AA) and nucleotide (nt) numbering for the α1 subunit in this study is based
on counting the startingmethionine or the first nucleotide of the start codon ATG as ‘1’. The
full-length human amino acid sequence used in this study has been aligned to the mouse equiv-
alent, and can be found in the supplement (S2 Fig).
Design of α1 subunit mutant library
The mutant library for the human α1 subunit was generated at Solvias AG (Switzerland) using
error-prone PCR based on the Genemorph II randommutagenesis kit and 500–1500 ng
Fig 1. Principles of SMRT sequencing and other NGS methods. Schematic drawing of SMRT sequencing (PacBio RSII) and other NGS techniques
such as an Illumina 454 reader. (A) The complete region covering the full-length coding sequence of the α1 subunit in each mutant cDNA (1371 bp) was
sequenced using SMRT sequencing, whereas only up to 300 bp stretches would have been read by an Illumina reader. (B) SMRT sequencing can link
each of three fictive mutations (red, blue, green) to the individual mutant, whereas this information is lost with Illumina sequencing due to the amplification
of short stretches only.
doi:10.1371/journal.pone.0163129.g001
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plasmid DNA. PCR products were purifiedwith a kit (Qiagen), and ligated into the parental
CMV-containing vector at an equivalent position.Mutant DNA plasmids were transformed
into Escherichia coli. 48 mutants were sequenced to calculate the mutation rate for this subset
using the HTMutagenesis Simulation Program (HT-MSP) as describedpreviously [1,2]. The
library with the desiredmutation rate (made from 1500 ng DNA) was up-scaled to obtain 2816
α1 subunit mutants in a 96 well format as previously described [1]. Glycerol stocks were frozen
to secure the library. The cDNA concentrations of all mutants were normalized to 40 ng/ μl.
Finally, 1 μl aliquots were taken from each mutant in order to create four pools (each contain-
ing 704 mutants), cDNAs were linearized, and subjected to SMRT sequencing.
‘Single molecule real time’ sequencing and data analysis
SMRT sequencing was performed based on the manufacturer’s protocol. High quality consen-
sus reads were extracted from the raw sequence signals using the SMRT analysis 2.3 patch 4 on
DNAnexus (Pacific Biosciences,USA). Reads were required to have four full passes and 90%
consistency in base calls, ensuring high quality initial reads. Single-molecule reads were aligned
to the wildtype α1 subunit sequence in order to identify mismatches in all reads. Examining
the total number of observed events for each possible specificmutation produced a bimodal
distribution of sequencing errors and truemutations. A new custom clustering algorithmwas
developed in order to control shifting of reads between clusters, and hence to overcome the
overlap of truemutations and sequencing noise (1–5 errors per molecule). For this, reads far-
thest from cluster medoid were placed into a background noise bin cluster, which allowed the
creation of new and destruction of existing clusters. The likelihood of observing the reads was
calculated over the foreground and background clusters, and sequences were reassigned until
convergence. Therefore, prior probability for observed reads per cluster was specified, and
terms for the inferred number of clusters without mutations and total reads falling into them
included. The resulting set of clusters represented 1929 sequences with at least one mutation
and 887 without, matching the expected Poisson distribution shape.
Cell culture and transfection
Parental human embryonic kidney (HEK)293 cells were obtained from American Type Culture
Collection (ATCC; CRL-1573), and cultured in Dulbecco’s modifiedEagle medium (DMEM)
supplemented with 10% (v/v) fetal calf serum (FCS) at 37°C in a 5% CO2/ 95% humidity atmo-
sphere. For passaging, cells were detached from the cell culture flask by washing with phos-
phate-buffered saline (PBS) without Ca2+/Mg2+, and brief incubation with 0.25% trypsin/ 1
mM EDTA. All solutions were from Life Technologies with the exception of FCS (Bioconcept).
For assay plates, cells were seeded into poly-D-lysine coated 384 well plates at 6000 cells/well in
40 μl culture media using an automated cell culture system (SelecT). 24 h later, cells were tran-
siently transfected using human muscle nAChR cDNA plasmids and Lipofectamine-LTX
(Invitrogen) using a recommended transfection protocol adapted to a 384 well format. Cells
were subjected to the ion flux assay or immunostaining 48 h post-transfection.
Ion flux assay
A Ca2+ flux assay for the human muscle nAChR channel was developed using an assay buffer
depleted of Na+ and the Ca2+-specific fluorogenic dye Fluo-4. Cells in the 384 wells were
washed twice with 80 μl assay buffer (20 mMHEPES, 0.9 mMKH2PO4, 0.8 mMMgSO4, 3 mM
CaCl2, 25 mM glucose, 4.5 mMKCl, 130 mMN-methyl-D-glucamine, pH to 7.4) using an
automated plate washer (Tecan), and leaving 20 μl residual buffer in the wells. 20 μl of assay
buffer containing 3.2 μM Fluo-4 acetomethylester and 2.5 mM probenecid were added, and
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cells incubated for 1 h at 37°C, 5% CO2, 95% humidity. Cells were washed with the previous
procedure and 20 μl residual buffer, and 15 min later the agonist epibatidine (or other) diluted
in assay buffer was injected in a 10 μl volume on a fluorescence imaging plate reader (FLIPR;
Molecular Devices). Inhibitors were added 30 min before applying an EC80 concentration of
epibatidine (determined by a separate experiment at the beginning of each experimental day,
and ranging from 100–270 nM), and in the case of α-BTX 0.1% BSA was added. α-BTXwas
purchased from R&D System, (+/-)-epibatidine and D-tubocurarine from Anawa, and ana-
toxin, cytisine, and dimethylphenylpiperazinium (DMPP) from Tocris. The intracellular de-
esterifiedCa2+ dye was excited at 488 nm. Baseline fluorescence signals (Fb) were recorded in 2
sec intervals for 10 sec using a band spectrum filter (510–570 nm), and fluorescence signals
after agonist addition for 60 sec in one sec intervals in order to determine the maximal fluores-
cence (Fmax). The FLIPR 2.2.3 software was used to visualize Ca2+ flux kinetics, and to extract
Fb and Fmax in order to calculate Ca2+ signals normalized to the resting Ca2+ level as (Fmax—
Fb)/ Fb. Concentration response curves (n = 3–5 per experiment) were analyzed by non-linear
regression curve fitting using the GraphPad Prism 6.04 software.
The library was split into sets of 88 mutants, each of which was expressed four times in the
four quadrants of a 384 well plate, allowing for testing of the same set of mutants in four differ-
ent conditions per plate. For the mutant screen, each plate quadrant corresponded to one con-
dition: (1) buffer control, (2) epibatidine EC80 control, (3) epibatidine EC80 + 0.1 μM α-BTX,
(4) epibatidine EC80 + 50 μM tubocurarine. Each assay plate contained also 32 control wells,
the latter expressing wildtypemuscle nAChR, and eight wells thereof subjected to each of the
four conditions as outlined above. Mutant hits were selected if they had a detectable epibatidine
response, and impaired inhibition of epibatidine-stimulated Ca2+ signals in the presence of
either α-BTX or tubocurarine compared with the wildtype channel control.
Immunostaining of the α1 subunit of muscle nAChR in transfected cells
Cells were fixed by adding PBS containing 4% (v/ v) paraformaldehyde and incubating at room
temperature (RT) for 20 min. Cells were washed three times with 50 μl PBS before blocking
with 10% FCS and 0.2% Triton X-100 in PBS for 30 min at RT. The blocking solution was dis-
carded before addition of an anti-α1 subunit-specificmonoclonal rat antibody (1:600; clone
210; Covance) in blocking buffer for 2.5 h at RT (the antibody recognizes the residues 371–386
of the α1 subunit). Cells were washed before incubation with an AlexaFluor488-conjugated
goat-anti–rat antibody (1:500; Life Technologies) in PBS containing 1% FCS and 0.02% Triton
X-100 for 1 hour at RT. Cells were washed, 50 μl PBS was added, and immunostainingmicros-
copy was performed using an Axiovert 25CFLmicroscope (Zeiss). Images were collectedwith
a LSM 510 laser system at a 40x magnification using excitation at 488 nm and measuring emis-
sion at 530 nm.
Results
Development of a functional HT assay for transiently transfected muscle
nAChRs
A Ca2+ flux assay suitable for HTmutant screening was established using an assay buffer
depleted of Na+, the nAChR-selective agonist epibatidine, and HEK293 cells. Co-transfection
of single plasmids for the four subunits of the muscle nAChR gave functional responses that
were too small for robust screening (S1B Fig), despite extensive attempts at optimizing trans-
fection and assay conditions (data not shown). Cloning of all four genes into the same plasmid,
however, improved Ca2+ signals by about three-fold. In order to enable screening of α1 subunit
HT Mutagenesis of the Muscle nAChR
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mutants in a separate expression vector, an additional triple subunit plasmid for wildtype β1, δ,
and ε subunits was constructed. Co-transfectionof the latter together with a single wildtype α1
subunit plasmid yielded epibatidine-stimulated Ca2+ responses that were as high as seen with
the quadruple gene plasmid. As expected, no significant signals were seen when transfecting
the triple β1-δ-ε plasmid in the absence of the α1 subunit. Optimal assay conditions included
seeding of 6000 cells in each of the 384 wells one day before transfection. For transfection 50
ng cDNA per well (DNA:lipofectamine ratio of 1:3.5) were used, and the functional assay was
performed two days post-transfection.
The pharmacology of the muscle nAChR was characterized in the transient Ca2+ flux assay,
and an EC50 of 90 nM (± 3.8, n = 5) for the agonist epibatidine was determined (S1C Fig). For
characterization of the two inhibitors, an EC80 concentration of epibatidine was used, which
was determined from a concentration response curve on each experimental day. For the wild-
type receptor, the IC50 values of α-BTX and tubocurarinewere found to be 2.9 nM (± 0.79,
n = 3) and 3.2 μM (± 2.4, 3 n = 3), respectively (S1D Fig), and concentrations of 0.1 μM α-BTX
and of 50 μM tubocurarinewere utilized in the mutant screen. The potency of epibatidine and
α-BTX are broadly consistent with literature data (EC50 of 260 nM and IC50 of 5 nM, respec-
tively) obtained by a similar technique in TE671 cells that endogenously express the human
fetal muscle nAChR type containing a γ instead of an ε subunit [14]. For tubocurarine, IC50’s
described for electrophysiology assays for the mouse adult muscle nAChR are 40–50 nM
[15,16], and differencesmight be species- and/or assay-related.
Generation of a muscle nAChR α1 subunit mutant library
The quality and coverage of a mutant library is defined by its size, coverage, mutation rate and
bias. The final library should preferably contain at least one mutant for each amino acid (‘total
coverage’), and ideally this mutation should occur as a single amino acidmutation, in the absence
of any other mutations in the same plasmid (‘unique coverage’). Small libraries require highmuta-
tion rates to achieve optimal total coverage, but this often results in the accumulation of muta-
tions, a drop in unique coverage and an increase in the risk of obtaining non-functional proteins.
Lowmutation rates give optimal unique coverage, but result in a high percentage of constructs
without mutations, and therefore require large library sizes that are more challenging to screen.
Given themaximal desired size of the library and the length of the protein or region of interest,
the optimal parameters can be calculated using the HT-MSP program as describedpreviously [1].
Error-prone PCR was used to generate a library of 2816 mutants for the 1371 bp-long α1
subunit coding sequence. Initial sequencing of a small subset of 48 mutants estimated the
mutation rate to be 1.15 mutations per kb. Given the size of our library, this mutation rate
would lead us to expect a unique coverage of 2.4 for the 457 amino acids in the α1 protein (e.g.
each position would be found to be mutated 2.4 times on average), and a total coverage for
each amino acid of 7.8. These estimates were found to be close to the actual measurements
obtained for the full library by SMRT sequencing (mutation rate of 1.27/kb, unique and total
coverages for each amino acid of 3.4 and 7.9, respectively). This increases our confidence in
using the HT-MSP program to optimize the ideal mutation rate from a small subset of mutants
before preparing a large mutant library (Fig 2). Furthermore, SMRT sequencing for the first
time enabled the characterization of all individual mutants of a large mutant library by its abil-
ity to sequence the full-length coding region of each plasmid in one reaction. Therefore, using
SMRT sequencing,multiple mutations within an individual plasmid can be detected, whereas
other NGS techniques can yield only the overall types of mutations within a library.
Detailed analysis of the mutant library sequences obtained by SMRT revealed that the distri-
bution of mutations had minimal bias as expected for error-prone PCR [17], with a slightly
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higher abundance of transitions as compared to transversions (ratio 1.5), and a slight bias for
the mutation of purines (A, T) over pyrimidines (G, C) (Table 1). At the nucleotide level 1269
Fig 2. Error-prone PCR mediated mutagenesis of the nAChR α1 subunit. (A) Number and distribution of mutations per clone
after error-prone PCR mediated mutagenesis of the nAChR α1 subunit. Black bars represent the number of mutations after
standard full-length Sanger sequencing of 48 mutants. Grey bars represent the sequenced mutational spectrum at a mutation rate
of 1.15/kb using HT-MSP [1]. (B) Expected number and distribution of nucleotide (grey) or amino acid (black) changes in the whole
library predicted by HT-MSP with a mutation rate of 1.15/kb. (C, D) Comparison of the distribution of nucleotide (C) and amino acid
(D) changes as predicted by HT-MSP (grey) and as measured by SMRT-sequencing (black) for the total library.
doi:10.1371/journal.pone.0163129.g002
Table 1. Nucleotide mutation properties of the α1 subunit mutant library based on SMRT
sequencing.
Transition (Ts) % Transversion (Tv) %
A!G 54 A! T 39
T! C 56 T! A 38
G! A 70 A! C 7.3
C! T 63 T!G 6.1
G! C 10
Bias Indicator C!G 9.5
Ts/Tv 1.5 G! T 20
(AT!GC) / (GC! AT) 0.8 C! A 28
A! N, T! N 53
G! N, C! N 47 Mutation Rate 1.27/kb
doi:10.1371/journal.pone.0163129.t001
HT Mutagenesis of the Muscle nAChR
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or 93% of the 1371 nucleotides have beenmutated between 1–21 times (Fig 3), resulting in a
complete coverage of the 457 amino acids (i.e. each amino acid was mutated at least once) (S3
Fig). 139 of the 143 possible types of amino acid mutations that can be achieved by one nucleo-
tide change per codon were found in the α1 subunit mutant library. This limitation in possible
codon changes results in a bias in the type of mutation that can be achieved for each amino
acid. Furthermore, the mutation frequency of each amino acid is determined by the number of
possibilities of codon changes that result in non-homologous amino acid changes, as well as
the mutational bias at the nucleotide level. The absolute number of mutations detected for each
amino acid type was between 100 and 328. The mutation frequency for each mutation type is
Fig 3. Mutational bias analyses of the α1 subunit mutant library. (A) Number of mutations for each of the 1371 nucleotides of the α1 subunit
sequence according to SMRT sequencing data. (B) Frequency of amino acid (AA) changes found in all 2816 α1 subunit mutants. The left column shows
the wildtype amino acid, whereas the top letters show the mutated amino acid with (*) representing a mutation into a stop codon. The absolute number
(n˚) of each type of amino acid within the α1 protein, and the absolute number of mutations for this amino acid are depicted on the right.
doi:10.1371/journal.pone.0163129.g003
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presented as the total number of mutations normalized to the absolute frequency of the amino
acid in the sequence. The highest mutation frequencies of 5.8% and 5.6% were found for the
tryptophan-to-arginine and cysteine-to-tyrosinemutations, respectively.
Functional screen of the muscle nAChR α1 subunit mutant library
The 2816 α1 subunit mutants were transiently expressed together with the β1δε wildtype sub-
units of the muscle nAChR, and the channels tested for sensitivity to the two selected competi-
tive blockers α-BTX and tubocurarine, in order to identify amino acids involved in binding of
the antagonists. Mutant hits were identified on the basis of raw kinetic Ca2+ traces as schemati-
cally shown in Fig 4. Epibatidine-responsive mutants were eventually selected as hits if they
were completely or in part resistant to blockade by the antagonists α-BTX and/or tubocurarine.
Mutants were considered as hits, only if they responded to the agonist (epibatidine) in the con-
trol wells, which indicated that the mutant channel was functional and reached the cell surface.
Around 40% of the mutants did not display a measurable agonist response. In other HT muta-
genesis projects, such as ANO1, a similar percentage was observed, and immunostaining
Fig 4. Illustration of the functional α1 mutant screen. (A) The muscle nAChR contains two α1 subunits that form a pentamer together with co-
transfected β1δε subunits. Ca2+ flux through channels containing wildtype or mutant α1 subunits was measured in a Na+-free buffer using the Ca2+-dye
Fluo4. Typical raw Ca2+ signal traces over time are presented for (B) the buffer control, (C) the agonist (epibatidine) control, (D) the blocker
tubocurarine, or (E) the blocker α-BTX (both added 30 min before adding the agonist, the injection of which is indicated by an arrow). Agonist-stimulated
Ca2+ signals of wildtype (Wt) muscle nAChR (black lines) are inhibited by tubocurarine or α-BTX. A non-functional mutant (green lines) is inactive in all
conditions, and does not show any Ca2+ signals. An α-BTX resistant mutant (blue lines) or tubocurarine resistant mutant (red lines) shows agonist
signals in the absence and presence of the respective blocker.
doi:10.1371/journal.pone.0163129.g004
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revealed that these mutant receptors were not transported to the cell surface [2]. Moreover,
buffer control wells for all mutants were inspected to make sure mutants were not spontane-
ously active. Following the first screening round, bacterial glycerol stocks of preliminary
mutant hits were used to prepare new cDNA plasmids for confirmation testing. Eight α1 sub-
unit mutant hits were confirmed and sequenced and these consisted of six unique mutants for
tubocurarine, one unique mutant for α-BTX, and one dual mutant (Table 2).
Analysis of the functional muscle nAChR α1 mutants
From Table 2 it is clear that Y233 and V275 are the main amino acid positions that were identi-
fied in our functionalHT mutagenesis screen. In order to gain insight into the quality of our
approach, we performed a full analysis of the SMRT data from our library to identify all clones
carryingmutations in any of the amino acid positions identified in the eight hits (Table 3 and
S1–S3 Tables). With regards to the V275 position (Table 3), our hits contained valine-to-
methionine or valine-to-glycinemutations. In the analysis we found two more V275 mutants
that were not picked up by the screen (SMRT-9 and SMRT-10). In these two clones, V275 was
mutated to alanine or to leucine and additional mutations were present. We do not know
whether the lack of detection of these two clones was due to the milder nature of the mutations
at position 275 (as it was changed to a different amino acid), or to a compensating or dominant
negative effect of the associatedmutations. A similar analysis of position Y233 (S1 Table) gives
a similar result: SMRT-20 (identical to Mutant-3) was missed in the screen, SMRT-22 was
non-functional (Y233 is mutated into a stop codon), and SMRT-21 has additional mutations
that could have rendered this mutant non-functional.
Interestingly, none of the mutants identified contained mutations at the residues known to
interact with α-BTX or tubocurarine [4]. SMRT sequencing allowed to retrieve systematically
from the library all the mutants at the 15 positions reported by Dellisanti et al. [9] to be
involved in the binding of α-BTX to the monomeric extracellular domain of the mouse α1 sub-
unit (S2 Fig). We found 130 mutants (24 of which are single amino acid mutants). None of
these was a hit in the functional screen (Table 4). We cannot link the identifiedmutants to
functional data. A lack of sensitivity of the functional screen could not explain why all these
mutants were not found. A possibility is that these mutations reduced or abolished epibatidine
sensitivity, and thus any effect on antagonist binding could not be detected.
Remarkably, all the positions identified are in the transmembrane domains: Y233 and I235
in M1, and V275 and V278 in M2. None of these residues are in the orthosteric binding site,
and it is clear that none of these residues can physically interact with tubocurarineor α-BTX
Table 2. Mutant hits identified from testing 2816 α1 subunit mutants in the functional screen.
Mutant Mutated AA (nt)
Mutant-1 V197A (T590C) V275M (G823A)
Mutant-2 D44N (G130A) silent (C402T) L278Q (T833A)
Mutant-3 Y233H (T697C) silent (T1083A)
Mutant-4 silent (C603A) Y233H (T697C)
Mutant-5 silent (T333C) V275M (G823A)
Mutant-6 V275G (T824G) S308F (C923T) L453S (T1358C)
Mutant-7 I235M (C705G)
Mutant-8 Y233N (T697A)
All mutant hits except mutant-7 were found in the tubocurarine screen. Mutant-6 and mutant-7 were identified in the α-BTX screen. Amino acid (AA)
changes are shown in bold. Nucleotide (nt) alterations are indicated in italics, and if not leading to an amino acid change (‘silent’) are shown in grey.
doi:10.1371/journal.pone.0163129.t002
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(S2 Fig). This begs the question of how they can reduce the channel sensitivity to these antago-
nists. Mutations here have been found to produce ‘Gain-of-Function’ (GoF) phenotype in
Table 3. SMRT analysis of all α1-V275 mutants in the library.
Mutant Mutated AA (nt) n˚
Reads
Mutant-1 V197A
(T590C)
V275M
(G823A)
10
Mutant-5 silent
(T333C)
V275M
(G823A)
12
Mutant-6 V275G
(T824G)
S308F
(C923T)
L453S
(T1358C)
11
SMRT-1 V111I
(A306G)
silent
(G331A)
V197A
(T590C)
14
SMRT-2 silent
(C321T)
silent
(C369T)
V197E
(T590A)
20
SMRT-3 W169*
(G506A)
V197E
(T590A)
7
SMRT-4 V197E
(T590A)
K262E
(A784G)
L293S
(T878C)
21
SMRT-5 W138R
(T412C)
V197E
(T590A)
15
SMRT-6 V197E
(T590A)
22
SMRT-7 silent
(T465C)
V197E
(T590A)
7
SMRT-8 V197M
(G589A)
silent
(G873A)
10
SMRT-9 silent
(G210A)
silent
(T498C)
M227T
(T680C)
V275A
(T824C)
S288P
(T862C)
T348A
(A1042G)
K360R
(A1079G)
13
SMRT-10 C212G
(T634G)
V275L
(G823C)
8
SMRT-11 silent
(A267C)
F155S
(T464C)
S308P
(T922C)
silent
(G996A)
12
SMRT-12 N84D
(A250G)
S308P
(T922C)
2
SMRT-13 K145E
(A433G)
F300V
(T898G)
S308T
(T922A)
silent
(C1014T)
M349K
(T1046A)
8
SMRT-14 silent
(C738A)
S308Y
(C923A)
M424V
(A1270G)
15
SMRT-15 P89S
(C265T)
silent
(C654T)
T257I
(C770T)
S308T
(T922A)
H326N
(C976A)
16
SMRT-16 H23L
(A68T)
S246P
(T736C)
L453S
(T1358C)
15
SMRT-17 I100F
(A298T)
T168A
(A502G)
silent
(C723A)
V281E
(T842A)
F300S
(T899C)
L453S
(T1358C)
N454K
(T1362A)
7
SMRT-18 Y132C
(A395G)
silent
(G690A)
V332A
(T995C)
K400E
(A1198G)
L453I
(T1357A)
13
SMRT-18 silent
(G147A)
N88K
(T264A)
K96I
(A287T)
L453I
(T1357A)
11
The 21 mutants include five α1-V275 mutants including mutant-1, mutant-5, and mutant-6, all hits discovered in the toxin screen. The library contained eight
mutants for α1-V197 (including three single mutants in this position) and five and four α1-S308 and α1-L453 mutants, respectively. The 18 ‘SMRT’ mutants
present in the library based on SMRT sequencing were not hits in the functional screen. Nucleotide alterations are indicated in italics, and silent amino acid
changes in grey. The number (n˚) of SMRT reads reflects the confidence of sequence determinations. (*) indicates a stop codon.
doi:10.1371/journal.pone.0163129.t003
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(mouse) muscle nAChR α1 (V275C) [18]. To test if the functional screen indeed identified
GoFmutants, the three most promising single amino acid mutants (Y233H, Y233H, V275M)
from the screen were chosen, and tested for a GoF phenotype.
Functional characterization of muscle nAChR α1 mutants
Concentration response curves for five knownmuscle nAChR agonists were determined in the
transient transfection Ca2+ assay for wildtype nAChR as well as the three selectedα1-mutants.
As can be seen in Fig 5 and Table 5, an increase in the potency of all five agonists was observed
for all three mutants. For the most potent agonists, epibatidine, anatoxin and DMPP, the
increase in potency was much greater with the α1-V275Mmutation (17-33-fold shift) than
with the Y233H (10-17-fold) or Y233N (2.9–4.4-fold) mutations. For cytisine and nicotine, the
least potent agonists, differences between the mutants were less pronounced. α1 subunit-spe-
cific immunostaining indicated that all three mutants were expressed at the cell surface at levels
similar to those achieved by wildtype α1 nAChRs. This suggests that the functionalmutagene-
sis screen indeed identifiedGoFmutants.
Discussion
Our study shows that the concept of HT mutagenesis can be applied not only to monomeric
proteins [1,2], but also to complex multimeric receptors such as the muscle nAChR. The feasi-
bility of a mutational screen depends on the feasibility of a functional assay based on transient
transfection of monomeric genes. For the pentamericmuscle nAChR this initially presented a
challenge, and novel multigene expression plasmids had to be designed in order to establish a
screening assay, as more classical transfection and assay optimization approaches proved inef-
fective. The aim of our study was to show the feasibility of the mutagenesis approach for the α1
Table 4. SMRT sequencing summary of α1 subunit mutants for published α-BTX binding site
residues.
AA n˚ Mutation (n˚) n˚ Single AA Mutant
V111 4 V111I (4) 0
Y113 7 Y113N (2), Y113H (2), Y113S (1), Y113C (1), Y113* (1) 1 (Y113H)
D119 6 D119E (3), D119V (2), D119G (1) 1 (D119E)
F120 11 F120S (5), F120L (4), F120C (1), F120I (1) 3 (2xF120L, F120S)
T168 11 T168S (4), T168A (3), T168I (2), T168N (2) 3 (T168S, T168I, T168S)
W169 15 W169R (5), W169G (1), W169C (1), W169* (8) 2 (W169R, W169G)
S207 12 S207T (4), S207P (4), S207F (3), S207A (1) 3 (2xS207P, S207T)
V208 9 V208A (3), V208E (2), V208M (2), V208L (1), V208G (1) 2 (V208M, V208A)
T209 10 T209S (5), T209A (2), T209I (2), T209P (1) 1 (T209S)
Y210 8 Y210H (5), Y210F (1), Y210* (2) 2 (Y210H, Y210F)
S211 5 S211T (3), S211F (1), S211P 1 (S211T)
C212 13 C212Y (4), C212S (3), C212R (3), C212G (2), C212* (1) 3 (C212S, C212R, C212Y)
P214 8 P214L (4), P214S (2), P214H (1), P214T (1) 2 (P214S, P214L)
P217 4 P217L (1), P217S (1), P217H (1), P217T (1) 0
Y218 7 Y218N (4), Y218S (2), Y218H (1) 0
Sum 130 24
Residues are corresponding to the 15 extracellular residues of the mouse α1 subunit described to interact
with α-BTX [9]; numbering converted to the human sequence used here. The 130 mutants present in the α1
subunit library were identified based on SMRT sequencing. (*) indicates a stop codon.
doi:10.1371/journal.pone.0163129.t004
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subunit, which is incorporated into the pentamer in two copies. Future studies can utilize the
same concept in order to expand to the β, δ, and ε subunits for a more thorough understanding
of structure-functionrelationships of the muscle nAChR.
Fig 5. α1-Y233 and α1-Y275 mutants enhance potencies of channel agonists. (A-E) Concentration response curves of five agonists measured
in the Ca2+ flux assay for transiently expressed wildtype and mutant α1-containing nAChRs. Basal fluorescence of each well was subtracted from
maximal signals, and used to normalize signals from each well. All curves represent averages (± s.d.) of three independent experiments, and each
experiment was conducted in triplicates. (F) Cells from the same transient transfections as used for the Ca2+ flux assay were immuno-stained and
confocal pictures taken at 40x magnifications with inlets depicting one enlarged single cell.
doi:10.1371/journal.pone.0163129.g005
Table 5. α1-Y233 and α1-Y275 mutants enhance the potency of nicotinic receptor agonists.
α1-Wt α1-Y233N α1-Y233H α1-V275M
Agonist EC50 [nM] EC50 [nM] Fold" EC50 [nM] Fold" EC50 [nM] Fold"
Epibatidine 72 ± 39 27 ± 11 2.9 ± 1.0 7 ± 0 10 ± 0.4 4 ± 1 17 ± 4.7
Anatoxin 191 ± 59 46 ± 1 4.4 ± 0.1 12 ± 1 17 ± 0.7 6 ± 2 33 ± 9.7
DMPP 1630 ± 203 705 ± 22 2.3 ± 0.1 161 ± 10 10 ± 0.6 67 ± 15 25 ± 5.2
Cytisine 2350 ± 367 1180 ± 76 2.0 ± 0.1 650 ± 93 3.7 ± 0.5 592 ± 153 4.1 ± 0.9
Nicotine 3650 ± 1040 1380 ± 96 2.7 ± 0.2 1390 ± 117 2.6 ± 0.2 557 ± 226 7.5 ± 3.5
Data represent average ± standard deviation (s.d.) values of three independent experiments with each experiment comprising n = 4 replicates per data
point.
doi:10.1371/journal.pone.0163129.t005
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The library of 2816 mutants contained mutants for each of the 457 amino acids of the
human α1 subunit, and unique and total coverages determined by SMRT sequencing 3.4 and
7.9, respectively. Despite the high quality of the library, mutational bias cannot be avoided.
Limitations arise because of the low probability of achieving two nucleotide changes within the
same amino acid codon, and indeed only single nucleotide changes per codon were detected in
our study. Furthermore, the extent of codon degeneracy is different for each amino acid. For
some amino acid there is no degeneracy, as they have only one codon (methionine and trypto-
phan). A single nucleotide change in this case must result in an amino acid change. Other
nucleotide changes are much more likely to remain silent (e.g. arginine, serine and leucine
which have six codons). 139 out of 143 possible residue changes that could be produced by a
single nucleotide mutation were found to be present in the mutant library. The four missing
changes are isoleucine to arginine, serine to tryptophan, arginine to methionine, and arginine
to threonine, which are all unlikely events due to codon restrictions. Altogether, this demon-
strates the importance of minimizing bias at the nucleotide level, given that the introduction of
further systematic bias is unavoidable at the amino acid level.
The functionalα1 subunit mutant screen was aimed at finding residues interacting with the
two orthosteric blockers α-BTX and/or tubocurarine.However, none of the mutant hits (D44/
L278, Y233, I235, V275) are in the known orthosteric binding site, and thus they do not overlap
with the residues that are known to interact with these two blockers [7–9]. The SMRT sequence
analysis showed that the mutant library had a broad coverage in this area, and included 130
mutants (24 of which are single amino acid mutants) of the 15 amino acids reported to interact
with α-BTX [9]. Thus lack of coverage cannot explain why these positions have not been iden-
tified. One explanation could be species-related pharmacological differences. For instance, at
the best characterisedα-BTX binding position T209 mouse receptors have a phenylalanine and
are very sensitive to α-BTX, whereas human receptors have a threonine and are less sensitive,
and mongoose and cobra receptors have an asparagine and are completely insensitive [7].
Hence, the type of amino acid introduced by mutation (for the human α1 mutant library the
only single amino acid mutant was T209S) can impact α-BTX interaction. For tubocurarine,
the greatest mutation effect reported in the literature for an α1 residue is seen with the Y218T
mutation, which decreases binding affinity at the high affinity site by 175-fold [8]. The mutant
library did not contain any single point mutant for Y218. Interestingly, other types of mutation
at Y218 are described to increase tubocurarine affinity [19], indicating that a broad spectrum
of amino acid changes is desirable for each residue. In the present study, 40% of tested mutants
did not show any detectable agonist response. This could be because the mutants may have not
folded properly, and were not displayed at the cell surface. This is a common situation in many
membrane proteins including ion channels, for which naturally occurring single amino acid
mutants are defective in folding and plasma membrane trafficking, and thus cause human dis-
eases [20,21]. Another possibility, besidesmisfolding, is that these mutants have lost the capa-
bility to respond to epibatidine. By definition, competitive antagonists interact with the same
site as the agonist. Work on the α and γ subunits of Torpedo AChR suggested substantial over-
lap between residues important for tubocurarinebinding and those important for agonist bind-
ing [19]. In addition to that, it is known that the complementary subunits are major
determinants of tubocurarine affinity [4], and it could be that most of the single mutations in
the α1 subunit have only minor effects and would be detectable only if associated with other
mutations of interacting residues in the α1 subunit, and/or in the δ/ε subunits.
Somewhat unexpectedly, the specificmutations identified by the screen were found to have
a GoFmode of action. For all three single amino acid mutants tested, we saw a significant
enhancement in the potencies of a panel of muscle nAChR agonists. As a result of the potency
shifts, the agonist concentration used in the screen to detect antagonist blockade became a
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saturating or supra-saturating concentration at the mutant channels. It is likely that this
increase in the effective concentration of the agonist gave rise to the apparent resistance to the
antagonists. Mutations at position V275 have been extensively described in the muscle nAChR
literature and shown to have a GoF phenotype, giving rise to spontaneous openings.Mutations
in this position in the related α7 nicotinic channel also give rise to a GoF phenotype [22,23].
This valine (13’ in transmembrane domain 2 (TM2)) is part of the hydrophobic girdle that
starts at leucine 9’. Mutations in the equivalent position in the human β1 (V266M, V266A) as
well as the ε subunit (V265A) give rise to a slow channel form of congenital myasthenia, dis-
playing slower closing rates, spontaneous openings and an increase in apparent acetylcholine
affinity [24,25]. Recently published further analysis of such β1 and ε subunit mutants revealed
an increase in gating efficiency, due to increased opening rate and decreased closing rate. This
study found the agonist affinity of mutant channels unchanged [26]. Our hits included another
TM2 mutation, L278Q (position 16’ in TM2) that is likely to be a GoFmutation [27], even
though this particularmutant had a secondmutation (D44N). The two remaining GoF
mutants identified are both located in the first TM domain of the α1 subunit (Y233N/H and
I235M; 3’ and 5’ in TM1 respectively). To our knowledge, the effect of mutations at these posi-
tions has not been previously described in the extensive literature on muscle nAChR, demon-
strating the value of our randommutagenesis approach. Ca2+ flux data do not allow a detailed
mechanistic analysis for a fast channel like the muscle nAChR, largely because of the slow
speed of agonist application by injection into the well and the limited time resolution. Never-
theless, the greater potency increase for the more potent agonists is precisely what one would
expect, if the mutations acted by facilitating receptor gating. This pattern is predicted using
receptor occupancymodels with minimal assumptions [28].
Beyond the first HT mutagenesis for a multimeric protein, the study also shows the strength
of detailed individual mutant sequence information obtained by SMRT sequencing.Not only
the type of residue mutations covered is accurately determined, but also the exact combinations
within each mutant. This corroborates the mutant interpretation, by helping us to identify the
most interesting mutations in hits containing more than one residue alteration. In the study
here, SMRT sequencing was performed based on four pools of the α1 subunit mutants follow-
ing the functionalmutant screen. Future mutagenesis studies could be advanced using bar-
coded PCR primers for each mutant. SMRT sequencing with barcoded samples has been
recently described [29,30]. This would enable to associate the SMRT sequence reads to each
individual mutant located in a multi-well plate, and therefore to directly link sequence infor-
mation with the functional signals.With such a set-up one could easily re-analyze potential
false-negativemutant hits in the assay without having to retest the whole mutant library.
Another possibility could be site-directedmutagenesis of each amino acid, which became
recently more affordable and allows generation of a library containing only single amino acid
mutants. In this context, one frequently sees alanine scans being performed, i.e. each residue is
mutated into alanine, in the hope that this most likely maintains the protein conformation
[31,32]. On the other hand, advantages and disadvantages of site-directed residue scans versus
randommutagenesis remain to be substantiated by further investigations.
Supporting Information
S1 Fig. Establishment of a Ca2+ flux assay for transiently expressedmuscle nAChRs. (A)
Schematic illustration of the cDNA plasmids used to transiently express the four wildtypemus-
cle nAChR subunits. (B) HEK293 cells were transfected with either a β1δε triple subunit plas-
mid, four single subunit plasmids (2:1:1:1 ratio), the quadruple α1β1δε subunit plasmid, or a
β1δε triple subunit plasmid with a single α1 subunit plasmid (1:1 ratio). 48 h after transfection,
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cells were challenged with 6 μM epibatidine, and Ca2+ responses derived. Each bar represents
the average (± s.d.) of four assay wells. (C) Typical epibatidine-stimulated concentration
response curve obtained fromHEK293 cells transiently transfected with the β1δε triple and
single α1 subunit plasmids (n = 5, ± s.d.) using the Ca2+ flux assay. EC50 and EC80 concentra-
tions are indicated. (D) Inhibitory concentration response curves of α-BTX and tubocurarine
(n = 4, ± s.d.) obtained with Ca2+ flux measurements. Inhibitors were added 30 min prior to
addition of epibatidine (EC80 concentration).
(TIF)
S2 Fig. Sequence alignment of human and mousemuscle nAChR α1 proteins. Indicated in
green are the β-sheets (β1-β10), in black the three ligand-binding loops (A-C), and in brown
transmembrane domains (TM)1-4. Blue arrows show the 15 mouse α1 residues described to
directly interact with α-BTX, and red arrows indicate the three residues that beared GoFmuta-
tions (Y233, I235, V275) in the present study.
(TIF)
S3 Fig. Amino acid and nucleotidemutations around α1-V275 based on SMRT sequencing.
(A) Number of mutants in the α1 subunit library within a corresponding 21-nucleotide stretch
around residue 275. Colors indicate the type of nucleotide introduced by mutation. (B) Num-
ber of amino acid mutants in the mutant library within a 19 residue stretch around valine 275.
Colors indicate the type of amino acid introduced by mutational change, and () indicates a
stop codon.
(TIF)
S1 Table. All six α1-Y233mutants present in the α1 subunit mutant library.Mutant-3,
mutant-4, and mutant-8 were discovered in the toxin screen, whereas the other three α1-Y233
mutants present in the library based on SMRT sequencing were not found. Nucleotide alter-
ations are indicated in italics, and silent amino acid changes in grey. The number (n°) of SMRT
reads reflects the confidence of sequence determinations. () indicates a stop codon.
(DOCX)
S2 Table. All 11 α1-I235 mutants present in the α1 subunit mutant library.Mutant-7 was
discovered in the toxin screen, whereas the other ten α1-I235 mutants present in the library
based on SMRT sequencing were not detected. Nucleotide alterations are indicated in italics,
and silent amino acid changes in grey. The number (n°) of SMRT reads reflects the confidence
of sequence determinations. () indicates a stop codon.
(DOCX)
S3 Table. All 11 α1-D44/L278mutants present in the α1 subunit mutant library.Mutant-2
was discovered in the toxin screen, whereas the other seven α1-D44 mutants and three α1-
L278 mutants present in the library based on SMRT sequencing were not detected. Nucleotide
alterations are indicated in italics, and silent amino acid changes in grey. The number (n°) of
SMRT reads reflects the confidence of sequence determinations. () indicates a stop codon.
(DOCX)
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